|
|
Volumn 8, Issue 4, 2009, Pages 271-272
|
|
Allergic rhinitis: Market evolution
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIHISTAMINIC AGENT;
AZELASTINE PLUS FLUTICASONE;
BILASTINE;
CETIRIZINE;
CICLESONIDE;
COL 118;
DESLORATADINE;
FLUTICASONE FUROATE;
FLUTICASONE PROPIONATE;
GENERIC DRUG;
HISTAMINE H1 RECEPTOR ANTAGONIST;
LEVOCETIRIZINE;
LORATADINE;
MOMETASONE FUROATE;
MONTELUKAST;
MP 2902;
NON PRESCRIPTION DRUG;
OMALIZUMAB;
OMNARES;
OX NLA;
RESPIRATORY TRACT AGENT;
STEROID;
UNCLASSIFIED DRUG;
V 0114;
ALLERGIC RHINITIS;
ARTICLE;
ASTHMA;
BEDTIME DOSAGE;
BIOLOGICAL THERAPY;
CLINICAL TRIAL;
COMBINATION CHEMOTHERAPY;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG FORMULATION;
DRUG INDICATION;
DRUG INDUSTRY;
DRUG MARKETING;
DRUG SAFETY;
ECONOMIC EVALUATION;
FOOD AND DRUG ADMINISTRATION;
HAY FEVER;
HEALTH INSURANCE;
HUMAN;
IMMUNOTHERAPY;
MERGERS AND ACQUISITIONS;
NOSE CONGESTION;
PERENNIAL RHINITIS;
PRESCRIPTION;
PRIORITY JOURNAL;
ANTI-ALLERGIC AGENTS;
DRUG INDUSTRY;
HUMANS;
MARKETING;
NONPRESCRIPTION DRUGS;
RHINITIS, ALLERGIC, PERENNIAL;
RHINITIS, ALLERGIC, SEASONAL;
|
|
EID: 64049087006
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd2762 Document Type: Article |
|
Times cited : (7)
|
|
References (4)
|
